Cellmid Ltd - Trending towards break-even
Cellmid Ltd (ASX:CDY)

Trending towards break-even

Published Oct 01, 2019

What happened?


Accelerating consumer health revenue growth:

Consumer health revenue growth of 30% in FY2019, up from 25% in FY2018.

Improved operating results:

Consumer health operating results improved with a 42% reduction in operating loss to $0.7 million, down from $1.2 million in FY2018.

Investing for global growth:

Significant investment in senior management team, distribution channels, e-commerce and digital market capabilities plus operational efficiencies.

Guidance confirmed:

Cellmid is on track to reach operating profitability in the consumer health business in FY2020.

CEO's summary

Maria Halasz CEO of Cellmid Ltd has provided a statement.
Maria Halasz
Maria Halasz
CEO, Cellmid Ltd

“FY2019 was a year of significant investment for Cellmid. We have expanded our distribution channels in the US and around the world, built our e-commerce and digital marketing infrastructure, and we have expanded our senior management capability for global growth. The benefit of these investments will flow through in FY2020 and beyond. We are now well positioned to take advantage of the large market opportunity for our first in class, best in class antiaging hair products.”

Download Announcement

View this announcement as well as our full profile on the company.

Comments

Share your thoughts about this announcement...

Similar articles
Independent test results for the Wondfo SARS-COV-2 Test
What's happened? Cellmid Limited (ASX:CDY) has announced that a validation study has been completed for the Wondfo SARS-...
1 year ago
Cellmid share placement raises $6m to fund SARS-V-2 diagnostic test roll out
What's happened? Cellmid Limited (ASX:CDY) has raised $6 million (before costs) via a share placement from institutional...
1 year ago
Cellmid enter into supply agreement for COVID-19 rapid diagnostic test
What's happened? Cellmid Ltd (ASX: CDY, “Cellmid”) have announced that it has entered into a supply agreement for a COVI...
1 year ago
Around the web
Reporting Season Round Up: The good times roll on for COVID beneficiary stocks
In 2021 many COVID beneficiary stocks actually dropped following their financial results, as investo...
via stockhead.com.au
Why are ASX-listed stocks PBH, HNG, DCC on investors’ radar today?
Highlights PointsBet has been appointed as Austin FC’s Exclusive Sportsbook Partner through an e...
via kalkinemedia.com
ASX Health Stocks: M&A winds blow as API gets an upgraded offer from Wesfarmers, jumps 15pc
The ASX 200 health stocks index (XHJ) has lifted by 0.46% at the time of writing, compared to the br...
via stockhead.com.au
Powered by  
  • Company
    Cellmid Ltd
  • Website
  • Sector
    Biotechnology
  • Industry
    Biotechnology
  • Code
    ASX:CDY
  • Socials
View Cellmid Ltd's Profile

How do I invest?

Considering investing in Cellmid Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:CDY

    On your online investment platform search for the stock ticker code ASX:CDY to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up